PMID- 38339284
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240212
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 16
IP  - 3
DP  - 2024 Jan 26
TI  - Impact of KIR-HLA Genotype on Natural-Killer-Cell-Based Immunotherapy for 
      Preventing Hepatocellular Carcinoma after Living-Donor Liver Transplantation.
LID - 10.3390/cancers16030533 [doi]
LID - 533
AB  - Natural killer (NK) cells have immunosurveillance potential in hepatocellular 
      carcinoma (HCC). We performed adaptive immunotherapy using donor-liver-derived 
      natural killer (NK) cells after living-donor liver transplantation (LDLT) to 
      prevent HCC recurrence. Dominant inhibitory signals tightly regulate NK cell 
      activity via human leukocyte antigen (HLA)-specific inhibitory receptors, such as 
      killer immunoglobulin-like receptors (KIRs). The functional recognition of HLA 
      through KIR raises the NK cell capacity, which is a process termed "licensing." 
      Here, we investigated the effect of polymorphic KIR-HLA genotypes on the efficacy 
      of NK-cell-based immunotherapy after LDLT. Seventy-seven Japanese recipients with 
      HCC who underwent LDLT and their corresponding donors between 1996 and 2016 were 
      enrolled in this study. The median follow-up period was 8.3 years. The HCC 
      recurrence risk was stratified using radiological and pathological assessments 
      according to the Milan criteria. Of the 77 recipients, 38 received immunotherapy. 
      Immunotherapy improves early post-transplantation survival and lowers the 
      recurrence rate in the intermediate-risk recipients. We analyzed the genotypes of 
      five inhibitory KIRs and HLA using sequence-specific polymorphism-based typing. 
      The polymorphic KIR-HLA genotype revealed that genetically vulnerable liver 
      transplant recipients with a poorly licensed NK genotype have an improved 
      prognosis by immunotherapy with donor-liver-derived NK cells. Thus, the 
      combination of recipient and donor KIR-HLA genotypes is worthy of attention for 
      further investigation, especially considering the clinical application of 
      NK-cell-based immunotherapy.
FAU - Tanimine, Naoki
AU  - Tanimine N
AUID- ORCID: 0000-0003-2744-9097
AD  - Department of Gastroenterological and Transplantation Surgery, Graduates School 
      of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, 
      Hiroshima 734-8551, Hiroshima, Japan.
AD  - Department of Surgery, Kure Medical Center, Chugoku Cancer Center, 3-1 
      Aoyama-cho, Kure 737-0023, Hiroshima, Japan.
FAU - Ohira, Masahiro
AU  - Ohira M
AUID- ORCID: 0000-0002-5433-5303
AD  - Department of Gastroenterological and Transplantation Surgery, Graduates School 
      of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, 
      Hiroshima 734-8551, Hiroshima, Japan.
FAU - Kurita, Emi
AU  - Kurita E
AD  - Division of Blood Transfusion Services, Hiroshima University Hospital, 1-2-3 
      Kasumi, Minami-ku, Hiroshima 734-8551, Hiroshima, Japan.
FAU - Nakano, Ryosuke
AU  - Nakano R
AD  - Department of Gastroenterological and Transplantation Surgery, Graduates School 
      of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, 
      Hiroshima 734-8551, Hiroshima, Japan.
FAU - Sakai, Hiroshi
AU  - Sakai H
AD  - Department of Gastroenterological and Transplantation Surgery, Graduates School 
      of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, 
      Hiroshima 734-8551, Hiroshima, Japan.
FAU - Tahara, Hiroyuki
AU  - Tahara H
AUID- ORCID: 0000-0002-4925-6037
AD  - Department of Gastroenterological and Transplantation Surgery, Graduates School 
      of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, 
      Hiroshima 734-8551, Hiroshima, Japan.
FAU - Ide, Kentaro
AU  - Ide K
AUID- ORCID: 0000-0002-2293-1688
AD  - Department of Gastroenterological and Transplantation Surgery, Graduates School 
      of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, 
      Hiroshima 734-8551, Hiroshima, Japan.
FAU - Kobayashi, Tsuyoshi
AU  - Kobayashi T
AUID- ORCID: 0000-0001-7364-1798
AD  - Department of Gastroenterological and Transplantation Surgery, Graduates School 
      of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, 
      Hiroshima 734-8551, Hiroshima, Japan.
FAU - Tanaka, Yuka
AU  - Tanaka Y
AD  - Department of Gastroenterological and Transplantation Surgery, Graduates School 
      of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, 
      Hiroshima 734-8551, Hiroshima, Japan.
FAU - Ohdan, Hideki
AU  - Ohdan H
AD  - Department of Gastroenterological and Transplantation Surgery, Graduates School 
      of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, 
      Hiroshima 734-8551, Hiroshima, Japan.
LA  - eng
GR  - JP23fk0210108/Japan Agency for Medical Research and Development/
PT  - Journal Article
DEP - 20240126
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC10854659
OTO - NOTNLM
OT  - adjuvant therapy
OT  - hepatocellular carcinoma
OT  - human leukocyte antigen
OT  - immunotherapy
OT  - killer immunoglobulin-like receptor
OT  - liver transplantation
OT  - natural killer cell
OT  - recurrence
COIS- The authors declare no conflicts of interest.
EDAT- 2024/02/10 10:53
MHDA- 2024/02/10 10:54
PMCR- 2024/01/26
CRDT- 2024/02/10 01:14
PHST- 2023/12/30 00:00 [received]
PHST- 2024/01/21 00:00 [revised]
PHST- 2024/01/25 00:00 [accepted]
PHST- 2024/02/10 10:54 [medline]
PHST- 2024/02/10 10:53 [pubmed]
PHST- 2024/02/10 01:14 [entrez]
PHST- 2024/01/26 00:00 [pmc-release]
AID - cancers16030533 [pii]
AID - cancers-16-00533 [pii]
AID - 10.3390/cancers16030533 [doi]
PST - epublish
SO  - Cancers (Basel). 2024 Jan 26;16(3):533. doi: 10.3390/cancers16030533.